Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology

Vasyl Beniuk; Vadym Goncharenko; Andrii Kurchenko; Oleksii Tatskyy; Sergii Konovalenko; Svitlana Vintoniuk; Sergii Melnikov; Kamil Nurimanov; Sergii Podpriatov

doi:doi:10.11648/j.iji.20200801.11

Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology

Vasyl Beniuk, Vadym Goncharenko, Andrii Kurchenko, Oleksii Tatskyy, Sergii Konovalenko, Svitlana Vintoniuk, Sergii Melnikov, Kamil Nurimanov, Sergii Podpriatov

Published in International Journal of Immunology (Volume 8, Issue 1)

Received: 7 February 2020 Accepted: 21 February 2020 Published: 2 March 2020

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The article provides evidence of clinical experience with the use of Arecur® for the treatment of endocervicitis and dysplasia of the cervix, endometrioma, chronic bacterial prostatitis, and for postoperative rehabilitation in patients after removal of hemorrhoids. Arecur® contains exogenous peptides of natural origin – anti-infective proteins of the group of defensins and RJP-1 and has antibacterial, antiviral, anti-inflammatory and antitumor activity. In the study groups, in which Arecur® was assigned to the patients, were reported significantly better clinical efficacy results. The ability of exogenous peptides to mobilize T-lymphocytes to identify and destroy infected and atypical cells determines the elimination of human papilloma virus and creates the conditions for reducing the risk of malignant cell transformation of cervical canal. Arecur®, by enhancing the immune supervision of ectopic endometrial cells, promotes regression of clinical symptoms and prolongation of inter-relapsing intervals in patients with endometriosis. In chronic bacterial prostatitis Arecur® increases the efficiency of etiotropic and symptomatic therapy. After surgical removal of hemorrhoid lesions, Arecur® provides more positive dynamics of rehabilitation, improves patients' quality of life and prevents complications. The obtained results allow us to reasonably recommend Arecur® as a medicine for anti-recurrent immunocorrection in gynecology, andrology and proctology.

Published in	International Journal of Immunology (Volume 8, Issue 1)
DOI	10.11648/j.iji.20200801.11
Page(s)	1-8
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Anti-Recurrent Immunocorrection, Exogenous Peptides, Arecur, Endocervicitis, Dysplasia, Human Papilloma Virus, Chlamydia, Endometrioma, Prostatitis, Hemorrhoids

References

[1]	Sun CQ, Arnold RS, Hsieh CL, Dorin JR, Lian F, Li Z, Petros JA. Discovery and mechanisms of host defense to oncogenesis: targeting the β-defensin-1 peptide as a natural tumor inhibitor. Cancer Biol Ther. 2019; 20 (6): 774-786.
[2]	Parvy JP, Yu Y, Dostalova A, Kondo S, Kurjan A, Bulet P, Lemaître B, Vidal M, Cordero JB. The antimicrobial peptide defensin cooperates with tumour necrosis factor to drive tumour cell death in Drosophila. Elife. 2019 Jul 30; 8: e45061.
[3]	Fruitwala S, El-Naccache DW, Chang TL. Multifaceted immune functions of human defensins and underlying mechanisms. Semin Cell Dev Biol. 2019 Apr; 88: 163-172.
[4]	Cheng, H. Y., Ning, M. X., Chen, D. K., & Ma, W. T. (2019). Interactions Between the Gut Microbiota and the Host Innate Immune Response Against Pathogens. Frontiers in immunology, 10, 607.
[5]	Kurchenko A. I., Beniuk VO, Potebnya GP, Kobis V. L., Tatskyi O. F., Neimark S. O. The role of exogenous peptides in the renewal of a full immune reaction in the conditions of the second immunodeficiency. Women's health. 2017; №1 (117). - P. 89-97.
[6]	Shypulin V, Stoliarova O, Konovalenko V, Tatskyy O, Didenko G, Konovalenko S. Study of the Exogenous Peptide Effect on the TGF-β1 Expression-A Risk Factor for the Hepatocellular Carcinoma Recurrence. American Journal of Biomedical and Life Sciences. Vol. 7, No. 4, 2019, pp. 73-78.
[7]	Litvinenko O. O, Tatskiy O. F, Konovalenko V. F, et al. Breast Cancer Relapse Prevention: Role of Anti-Relapsing Immunocorrection. Cancer Sci Res. 2019; 2 (2); 1-6.
[8]	Sachse K, Laroucau K, Riege K, Wehner S, Dilcher M, Creasy HH, Weidmann M, Myers G, Vorimore F, Vicari N, et al. Evidence for the existence of two new members of the family Chlamydiaceae and proposal of Chlamydia avium sp. nov. And Chlamydia gallinacea sp. nov. Syst Appl Microbiol 2014; 37: 79–88.
[9]	Williamson A. L. Chattopadhyay K., Hazra A., Dandara C. The combined risks ofreduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South Africa. BMC Cancer. 2015; 15: 680.
[10]	Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136: 189–197.
[11]	D. Wohlmeister, D. Barreto Vianna, Vi. Etges Helfer, F. Gimenes, M. Lopes Consolaro, R. Bones Barcellos, M. L. Rossetti, L. Calil, A. Buffon, D. A. Pilger. Association of human papillomavirus and Chlamydia trachomatis with intraepithelial alterations in cervix samples. Mem Inst Oswaldo Cruz. 2016 Feb; 111 (2): 106–113.
[12]	Melnikov SM, Tatskyi O. F. A new look at endometriosis: the role of restoring of full immune surveillance over ectopic cells of the endometrium. Women's health. 2017; № 7 (123). - P. 99-107.
[13]	Hou XX, Wang XQ, Li DJ. Roles of regulatory T Cells in pathogenesis of endometriosis. Reprod Dev Med 2019; 3: 117-23.
[14]	Yang S, Wang H, Li D, Li M. Role of Endometrial Autophagy in Physiological and Pathophysiological Processes. J Cancer. 2019 Jun 9; 10 (15): 3459-3471.
[15]	Vallvé-Juanico J, Houshdaran S, Giudice LC. The endometrial immune environment of women with endometriosis. Hum Reprod Update. 2019 Sep 11; 25 (5): 564-591.
[16]	Gorpinchenko I. I., Migov V. G. Treatment of patients with chronic calculous prostatitis using a peptide biostimulator Prostatilen: first results and prospects // Men's Health. - No 2 (45) 2013. - P. 37–40.
[17]	Zaseda Y. I., Solomenny RI, Ganushchak A. V. The experience of radical conservative treatment of chronic calculous-fibrous and fibrous-calculous prostatitis // Ukrainian journal "Healthy, gender and psychosomatic medicine." - 2016.-- No. 1 (03). - P. 34–43.
[18]	Zaseda Y. I., Tatskyi O. F. The effect of tissue accumulation of exogenous peptides is the key to understanding the mechanisms of harmonization of the immune homeostasis of patients with chronic bacterial prostatitis. Health of the man. 2017. № №1 (60). - P. 51 - 56.
[19]	Podpriatov S, Apostolov V, Tatskyy O, Konovalenko S. Konovalenko V. Аngioprotective properties of exogenous peptides. Practitioner №1 (8)-2019; 20-24.

Cite This Article

Plain Text BibTeX RIS

APA Style

Vasyl Beniuk, Vadym Goncharenko, Andrii Kurchenko, Oleksii Tatskyy, Sergii Konovalenko, et al. (2020). Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. International Journal of Immunology, 8(1), 1-8. https://doi.org/10.11648/j.iji.20200801.11

Copy | Download

ACS Style

Vasyl Beniuk; Vadym Goncharenko; Andrii Kurchenko; Oleksii Tatskyy; Sergii Konovalenko, et al. Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. Int. J. Immunol. 2020, 8(1), 1-8. doi: 10.11648/j.iji.20200801.11

Copy | Download

AMA Style

Vasyl Beniuk, Vadym Goncharenko, Andrii Kurchenko, Oleksii Tatskyy, Sergii Konovalenko, et al. Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. Int J Immunol. 2020;8(1):1-8. doi: 10.11648/j.iji.20200801.11

Copy | Download

@article{10.11648/j.iji.20200801.11,
  author = {Vasyl Beniuk and Vadym Goncharenko and Andrii Kurchenko and Oleksii Tatskyy and Sergii Konovalenko and Svitlana Vintoniuk and Sergii Melnikov and Kamil Nurimanov and Sergii Podpriatov},
  title = {Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology},
  journal = {International Journal of Immunology},
  volume = {8},
  number = {1},
  pages = {1-8},
  doi = {10.11648/j.iji.20200801.11},
  url = {https://doi.org/10.11648/j.iji.20200801.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20200801.11},
  abstract = {The article provides evidence of clinical experience with the use of Arecur® for the treatment of endocervicitis and dysplasia of the cervix, endometrioma, chronic bacterial prostatitis, and for postoperative rehabilitation in patients after removal of hemorrhoids. Arecur® contains exogenous peptides of natural origin – anti-infective proteins of the group of defensins and RJP-1 and has antibacterial, antiviral, anti-inflammatory and antitumor activity. In the study groups, in which Arecur® was assigned to the patients, were reported significantly better clinical efficacy results. The ability of exogenous peptides to mobilize T-lymphocytes to identify and destroy infected and atypical cells determines the elimination of human papilloma virus and creates the conditions for reducing the risk of malignant cell transformation of cervical canal. Arecur®, by enhancing the immune supervision of ectopic endometrial cells, promotes regression of clinical symptoms and prolongation of inter-relapsing intervals in patients with endometriosis. In chronic bacterial prostatitis Arecur® increases the efficiency of etiotropic and symptomatic therapy. After surgical removal of hemorrhoid lesions, Arecur® provides more positive dynamics of rehabilitation, improves patients' quality of life and prevents complications. The obtained results allow us to reasonably recommend Arecur® as a medicine for anti-recurrent immunocorrection in gynecology, andrology and proctology.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology
AU  - Vasyl Beniuk
AU  - Vadym Goncharenko
AU  - Andrii Kurchenko
AU  - Oleksii Tatskyy
AU  - Sergii Konovalenko
AU  - Svitlana Vintoniuk
AU  - Sergii Melnikov
AU  - Kamil Nurimanov
AU  - Sergii Podpriatov
Y1  - 2020/03/02
PY  - 2020
N1  - https://doi.org/10.11648/j.iji.20200801.11
DO  - 10.11648/j.iji.20200801.11
T2  - International Journal of Immunology
JF  - International Journal of Immunology
JO  - International Journal of Immunology
SP  - 1
EP  - 8
PB  - Science Publishing Group
SN  - 2329-1753
UR  - https://doi.org/10.11648/j.iji.20200801.11
AB  - The article provides evidence of clinical experience with the use of Arecur® for the treatment of endocervicitis and dysplasia of the cervix, endometrioma, chronic bacterial prostatitis, and for postoperative rehabilitation in patients after removal of hemorrhoids. Arecur® contains exogenous peptides of natural origin – anti-infective proteins of the group of defensins and RJP-1 and has antibacterial, antiviral, anti-inflammatory and antitumor activity. In the study groups, in which Arecur® was assigned to the patients, were reported significantly better clinical efficacy results. The ability of exogenous peptides to mobilize T-lymphocytes to identify and destroy infected and atypical cells determines the elimination of human papilloma virus and creates the conditions for reducing the risk of malignant cell transformation of cervical canal. Arecur®, by enhancing the immune supervision of ectopic endometrial cells, promotes regression of clinical symptoms and prolongation of inter-relapsing intervals in patients with endometriosis. In chronic bacterial prostatitis Arecur® increases the efficiency of etiotropic and symptomatic therapy. After surgical removal of hemorrhoid lesions, Arecur® provides more positive dynamics of rehabilitation, improves patients' quality of life and prevents complications. The obtained results allow us to reasonably recommend Arecur® as a medicine for anti-recurrent immunocorrection in gynecology, andrology and proctology.
VL  - 8
IS  - 1
ER  -

Copy | Download

Author Information

Vasyl Beniuk

Department of Obstetrics and Gynecology, Bogomolets National Medical University, Kyiv, Ukraine
Vadym Goncharenko

Department of Obstetrics and Gynecology, Bogomolets National Medical University, Kyiv, Ukraine
Andrii Kurchenko

Department of Clinical Immunology, Allergology and Medical Genetics, Bogomolets National Medical University, Kyiv, Ukraine
Oleksii Tatskyy

International Institute of Biotherapy, Kyiv, Ukraine
Sergii Konovalenko

Department of Monitoring of Tumor Process and Therapy Design, RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
Svitlana Vintoniuk

City Maternity Hospital, Ivano-Frankivsk, Ukraine
Sergii Melnikov

Department of Restorative Urology and Innovative Technologies, Institute of Urology AMS of Ukraine, Kyiv, Ukraine
Kamil Nurimanov

Department of Sexology and Andrology, Institute of Urology AMS of Ukraine, Kyiv, Ukraine
Sergii Podpriatov

Center for Electric Welding Surgery and New Surgical Technologies, Kyiv, Ukraine

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Vasyl Beniuk, Vadym Goncharenko, Andrii Kurchenko, Oleksii Tatskyy, Sergii Konovalenko, et al. (2020). Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. International Journal of Immunology, 8(1), 1-8. https://doi.org/10.11648/j.iji.20200801.11

Copy | Download

ACS Style

Vasyl Beniuk; Vadym Goncharenko; Andrii Kurchenko; Oleksii Tatskyy; Sergii Konovalenko, et al. Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. Int. J. Immunol. 2020, 8(1), 1-8. doi: 10.11648/j.iji.20200801.11

Copy | Download

AMA Style

Vasyl Beniuk, Vadym Goncharenko, Andrii Kurchenko, Oleksii Tatskyy, Sergii Konovalenko, et al. Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. Int J Immunol. 2020;8(1):1-8. doi: 10.11648/j.iji.20200801.11

Copy | Download

@article{10.11648/j.iji.20200801.11,
  author = {Vasyl Beniuk and Vadym Goncharenko and Andrii Kurchenko and Oleksii Tatskyy and Sergii Konovalenko and Svitlana Vintoniuk and Sergii Melnikov and Kamil Nurimanov and Sergii Podpriatov},
  title = {Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology},
  journal = {International Journal of Immunology},
  volume = {8},
  number = {1},
  pages = {1-8},
  doi = {10.11648/j.iji.20200801.11},
  url = {https://doi.org/10.11648/j.iji.20200801.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20200801.11},
  abstract = {The article provides evidence of clinical experience with the use of Arecur® for the treatment of endocervicitis and dysplasia of the cervix, endometrioma, chronic bacterial prostatitis, and for postoperative rehabilitation in patients after removal of hemorrhoids. Arecur® contains exogenous peptides of natural origin – anti-infective proteins of the group of defensins and RJP-1 and has antibacterial, antiviral, anti-inflammatory and antitumor activity. In the study groups, in which Arecur® was assigned to the patients, were reported significantly better clinical efficacy results. The ability of exogenous peptides to mobilize T-lymphocytes to identify and destroy infected and atypical cells determines the elimination of human papilloma virus and creates the conditions for reducing the risk of malignant cell transformation of cervical canal. Arecur®, by enhancing the immune supervision of ectopic endometrial cells, promotes regression of clinical symptoms and prolongation of inter-relapsing intervals in patients with endometriosis. In chronic bacterial prostatitis Arecur® increases the efficiency of etiotropic and symptomatic therapy. After surgical removal of hemorrhoid lesions, Arecur® provides more positive dynamics of rehabilitation, improves patients' quality of life and prevents complications. The obtained results allow us to reasonably recommend Arecur® as a medicine for anti-recurrent immunocorrection in gynecology, andrology and proctology.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology
AU  - Vasyl Beniuk
AU  - Vadym Goncharenko
AU  - Andrii Kurchenko
AU  - Oleksii Tatskyy
AU  - Sergii Konovalenko
AU  - Svitlana Vintoniuk
AU  - Sergii Melnikov
AU  - Kamil Nurimanov
AU  - Sergii Podpriatov
Y1  - 2020/03/02
PY  - 2020
N1  - https://doi.org/10.11648/j.iji.20200801.11
DO  - 10.11648/j.iji.20200801.11
T2  - International Journal of Immunology
JF  - International Journal of Immunology
JO  - International Journal of Immunology
SP  - 1
EP  - 8
PB  - Science Publishing Group
SN  - 2329-1753
UR  - https://doi.org/10.11648/j.iji.20200801.11
AB  - The article provides evidence of clinical experience with the use of Arecur® for the treatment of endocervicitis and dysplasia of the cervix, endometrioma, chronic bacterial prostatitis, and for postoperative rehabilitation in patients after removal of hemorrhoids. Arecur® contains exogenous peptides of natural origin – anti-infective proteins of the group of defensins and RJP-1 and has antibacterial, antiviral, anti-inflammatory and antitumor activity. In the study groups, in which Arecur® was assigned to the patients, were reported significantly better clinical efficacy results. The ability of exogenous peptides to mobilize T-lymphocytes to identify and destroy infected and atypical cells determines the elimination of human papilloma virus and creates the conditions for reducing the risk of malignant cell transformation of cervical canal. Arecur®, by enhancing the immune supervision of ectopic endometrial cells, promotes regression of clinical symptoms and prolongation of inter-relapsing intervals in patients with endometriosis. In chronic bacterial prostatitis Arecur® increases the efficiency of etiotropic and symptomatic therapy. After surgical removal of hemorrhoid lesions, Arecur® provides more positive dynamics of rehabilitation, improves patients' quality of life and prevents complications. The obtained results allow us to reasonably recommend Arecur® as a medicine for anti-recurrent immunocorrection in gynecology, andrology and proctology.
VL  - 8
IS  - 1
ER  -

Copy | Download